- Home
- GYRE
as 05-09-2025 10:37am EST
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 897.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 104.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.11 - $19.00 | Next Earning Date: | 05-19-2025 |
| Revenue: | $105,757,000 | Revenue Growth: | -6.78% |
| Revenue Growth (this year): | 22.01% | Revenue Growth (next year): | 88.14% |
Stock Insider Trading Activity of Gyre Therapeutics Inc. (GYRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ma Songjiang | GYRE | President | Mar 21 '25 | Sell | $10.00 | 174 | $1,740.00 | 2,824,844 | |
| Ma Songjiang | GYRE | President | Mar 19 '25 | Sell | $10.11 | 4,000 | $40,440.00 | 2,824,844 | |
| Ma Songjiang | GYRE | President | Mar 17 '25 | Sell | $11.17 | 2,242 | $26,658.08 | 2,824,844 | |
| Ma Songjiang | GYRE | President | Mar 13 '25 | Sell | $12.06 | 4,000 | $48,220.00 | 2,824,844 | |
| Ma Songjiang | GYRE | President | Mar 11 '25 | Sell | $11.57 | 4,000 | $46,280.00 | 2,824,844 | |
| Ma Songjiang | GYRE | President | Mar 7 '25 | Sell | $11.36 | 4,000 | $40,776.11 | 2,824,844 | |
| Ma Songjiang | GYRE | President | Mar 5 '25 | Sell | $10.89 | 4,000 | $43,560.00 | 2,824,844 | |
| Ma Songjiang | GYRE | President | Mar 3 '25 | Sell | $11.05 | 4,000 | $44,180.00 | 2,824,844 | |
| Ma Songjiang | GYRE | President | Feb 27 '25 | Sell | $11.37 | 4,000 | $45,480.00 | 2,824,844 | |
| Ma Songjiang | GYRE | President | Feb 25 '25 | Sell | $11.50 | 4,000 | $46,000.00 | 2,824,844 |
Latest Gyre Therapeutics Inc. News
GYRE Breaking Stock News: Dive into GYRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 hours ago
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Simply Wall St.
2 days ago
A Note On Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE and Debt To Equity
GlobeNewswire
a month ago
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
Simply Wall St.
a month ago
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings
GlobeNewswire
a month ago
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
Simply Wall St.
2 months ago
Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
2 months ago
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Simply Wall St.
2 months ago
Exploring High Growth Tech Stocks In The US March 2025
Compare GYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GYRE Gyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.